ADC Therapeutics SA Form 6-K
Reporting period: Form 6-K filed November 2, 2022, for the month of November 2022. The filing identifies ADC Therapeutics SA as a Swiss foreign private issuer filing annual reports on Form 20-F.
Business Context and Financial Information
The submitted text contains the filing cover page only and does not include operating results, financial statements, revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes and Outlook
The filing references Exhibit 99.1, described as a press release dated November 2, 2022, but the press release content is not included in the provided text. Accordingly, the filing text does not provide clear information on material changes, guidance, management commentary, risks, contingencies, or unusual items.
Key Facts to Verify
- Obtain and review Exhibit 99.1, the November 2, 2022 press release.
- Verify whether the referenced press release contains financial results, clinical or regulatory updates, guidance, financing activities, or other material disclosures.
- Review the company’s applicable Form 20-F and subsequent reports for complete financial and liquidity information.